SE486-11
SE486-11 is an orally active USP5 inhibitor. SE486-11 increases free polyubiquitin chains and promotes the ubiquitination and degradation of MYCN. The combination of SE486-11 with SAHA (HY-10221) synergistically induces Apoptosis. SE486-11 can be used in research related to MYCN-driven neuroblastoma.
For research use only. We do not sell to patients.
- CAS No.: 305333-99-7
- Formula: C26H20N4O
- Molecular Weight:404.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Kelly | IC50 |
34.4 μM
|
Cytotoxicity against human neuroblastoma Kelly cells by Alamar Blue cell viability assay.
Cytotoxicity against human neuroblastoma Kelly cells by Alamar Blue cell viability assay.
|
37060785 |
In Vitro
SE486-11 (1:5 ratio with SAHA) binds purified full-length USP5 protein with a Kd of 159 nM, over 100-fold higher affinity than SAHA alone[1].
SE486-11 does not exhibit measurable binding affinity to purified full-length USP5 protein in an MST assay, as a dose-response kinetic curve could not be fitted[2].
SE486-11 (5-10 µM; 48-72 h) causes synergistic cytotoxicity in MYCN-amplified neuroblastoma cells (SK-N-BE(2)-C, Kelly, CHP134, IMR-32, LAN-1) and MDA-MB-231 breast cancer cells, with limited effects on normal human fibroblasts (WI-38, MRC-5)[1].
SE486-11 (5 µM; 24-72 h) reduces clonogenic colony formation (number and size) in MYCN-amplified SK-N-BE(2)-C and Kelly neuroblastoma cells[1].
SE486-11 inhibits the viability of SK-N-BE(2)-C and Kelly human neuroblastoma cells with IC50 values of 41.8 μM and 34.4 μM, respectively[2].
SE486-11 enhances the effectiveness of HDAC inhibitors in neuroblastoma cells by increasing MYCN ubiquitination via modulation of USP5[2].
SE486-11 (5 µM; 72 h) synergistically induces apoptosis in MYCN-amplified SK-N-BE(2)-C and Kelly neuroblastoma cells, but not in normal WI-38 and MRC-5 human fibroblasts[1].
SE486-11 (5 µM; 48 h) increases mitochondrial depolarisation in MYCN-amplified SK-N-BE(2)-C and Kelly neuroblastoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 breast cancer cells, SK-N-BE(2)-C and Kelly MYCN-amplified neuroblastoma cells, WI-38 and MRC-5 normal human fibroblasts, panel of MYCN-amplified (CHP134, IMR-32, LAN-1) and non-amplified (SH-SY5Y, SK-N-AS, SK-N-FI) neuroblastoma cells
-
Concentration:10 µM (with 1.9 µM SAHA, MDA-MB-231 cells); 5 µM (with 1 µM SAHA, SK-N-BE(2)-C, Kelly, WI-38, MRC-5 cells and neuroblastoma cell panel)
-
Incubation Time:48 h (MDA-MB-231 cells and neuroblastoma cell panel); 72 h (SK-N-BE(2)-C, Kelly, WI-38, MRC-5 cells)
-
Result:Reduced MDA-MB-231 cell viability to <40% when used with 1.9 µM SAHA for 48 h, while maintaining >70% viability when used alone.
Caused synergistic cytotoxicity (combination index <1) and reduced cell viability far below single agents in MYCN-amplified neuroblastoma cells when used with 1 µM SAHA for 72 h.
Exhibited limited cytotoxicity in normal WI-38 and MRC-5 fibroblasts when used with 1 µM SAHA for 72 h.
Caused the greatest viability reduction in MYCN-amplified neuroblastoma lines compared to non-amplified lines when used with 1 µM SAHA for 48 h.
-
Cell Line:SK-N-BE(2)-C and Kelly MYCN-amplified neuroblastoma cells, WI-38 and MRC-5 normal human fibroblasts
-
Concentration:5 µM (with 1 µM SAHA)
-
Incubation Time:72 h
-
Result:Significantly increased the percentage of cells in early and late apoptosis in SK-N-BE(2)-C and Kelly cells compared to single agents or DMSO control.
Did not induce apoptosis in normal WI-38 and MRC-5 fibroblasts.
In Vivo
Combination treatment with SE486-11 (30 mg/kg; p.o.; daily; 7 days) and SAHA reduces tumour size and lowers MYCN, USP5, and proliferation marker PCNA levels in MYCN-transgenic zebrafish with neuroblastoma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TH-MYCN+/+ (female, 3 weeks old, transgenic spontaneously developing neuroblastoma)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; 5 days on/2 days off; 21 days
-
Result:Reduced tumour formation to the extent that no tumour tissue remained for histopathological analysis.
-
Animal Model:dβh:EGFP-MYCN (0.5-1.5 years old, transgenic GFP-positive neuroblastoma)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Caused a reduction in GFP-positive tumour size from day 1 to day 7.
Reduced MYCN, USP5, and PCNA protein levels in tumour tissue compared with vehicle control.
Chemical Information
-
CAS No. 305333-99-7
-
Molecular Weight 404.46
-
Formula C26H20N4O
-
SMILES
CC1=C(C#N)C2=NC3=C(C=CC=C3)N2C(NC4=CC=C(O)C=C4)=C1CC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)